Genucel®With Plant Stem Cell Technology

Description: A polyclonal antibody for HSC70 from Plant | Wheat (Triticum spp.) | Pea (Pisum sativum). The antibody is produced in rabbit after immunization with Plant HSC70 purified from wheat germ. The Antibody is tested and validated for WB, ELISA, IP assays with the following recommended dilutions: WB (1:50000). This HSC70 antibody is unconjugated.

Description: A polyclonal antibody for HSP17.6 from Plant | Arabidopsis thaliana. The antibody is produced in rabbit after immunization with Plant Recombinant protein Arabidopsis thaliana Hsp17.6 CI (class one) . The Antibody is tested and validated for WB assays with the following recommended dilutions: WB (1:1000). This HSP17.6 antibody is unconjugated.

Description: A polyclonal antibody for HSP17.7 from Plant | Arabidopsis thaliana. The antibody is produced in rabbit after immunization with Plant Full length recombinant protein HSP17.7 produced in E.coli and purified by conventional methods (no affinity tag). The Antibody is tested and validated for WB assays with the following recommended dilutions: WB (1:1000). This HSP17.7 antibody is unconjugated.

Description: A polyclonal antibody for HSP21 from Plant | Arabidopsis thaliana. The antibody is produced in rabbit after immunization with Plant Recombinant Hsp21 protein derived from the sequence of Arabidopsis thaliana. The Antibody is tested and validated for WB assays with the following recommended dilutions: WB (1:3000). This HSP21 antibody is unconjugated.

Description: A Monoclonal antibody against Human PAX6 (Stem Cell Marker) - With BSA and Azide. The antibodies are raised in Mouse and are from clone SPM612. This antibody is applicable in IHC, IF, FC

Description: RIPA Buffer extracts proteins from cultured mammalian cells for various downstream applications.

Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed. The RAPAd® Universal Adenoviral Expression System (# VPK-250) contains a promoterless shuttle vector to allow you to insert the promoter of your choice along with your gene of interest to maximize gene expression.

Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed.

Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed.

Description: Making an adenovirus with traditional recombinant methods takes 2-3 months and requires tedious plaque recombination. More recent technologies have shortened this time somewhat, but still produce relatively high amounts of wild type (replication-competent) plaques, levels of which increase with serial amplification. The RAPAd® Adenoviral Expression Systems produce recombinant adenovirus with substantially reduced wild-type virus, while considerably shortening the production time to 2-3 weeks. Serial amplification of adenovirus produced using the RAPAd® system does not significantly increase replication-competent adenovirus levels. The system uses a backbone vector from which the 5' ITR, packaging signal and E1 sequences have been removed.